Quarterly ResultAug 4, 2026, 04:11 PM
Syndax Q2 Revenue +91.8% to $72.8M; Net Loss Narrows to $49.4M
AI Summary
Syndax Pharmaceuticals reported a significant increase in total revenues for Q2 2026, rising 91.8% to $72.8 million, driven by strong product and collaboration revenue growth. The company also narrowed its net loss to $49.4 million, an improvement from $71.8 million in the prior year. Cash and cash equivalents substantially increased to $336.5 million, partly due to proceeds from a $250 million convertible note issuance.
Key Highlights
- Total revenues for Q2 2026 increased 91.8% to $72.8 million.
- Net loss for Q2 2026 narrowed to $49.4 million from $71.8 million in Q2 2025.
- Basic and diluted loss per share improved to $(0.55) from $(0.83) in Q2 2025.
- Cash and cash equivalents rose to $336.5 million as of June 30, 2026.
- Received $250.0 million in proceeds from a convertible note issuance.
- Product revenue, net, grew 91.3% to $54.7 million in Q2 2026.
- Collaboration revenue, net, increased 93.3% to $18.1 million in Q2 2026.
Price Impact
More from SNDX